Clinical Trial Detail

NCT ID NCT02744287
Title Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bellicum Pharmaceuticals
Indications

prostate cancer

stomach cancer

gastroesophageal junction adenocarcinoma

pancreatic cancer

Therapies

BPX-601 + Rimiducid

Age Groups: adult senior

No variant requirements are available.